Pss22 - Economic Burden of Disease of Hidradenitis Suppurativa in Finland: Results From the Hi-Fi Study

Abstract

OBJECTIVES: Lichen planus is a dermatological disease characterized by itchy reddish-purple polygon-shaped skin lesions. The aim of our study was to calculate the annual health insurance treatment cost of lichen planus in Hungary. METHODS: The data were derived from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFA), the only health care financing agency in Hungary. We analyzed the number of patients and the health insurance treatment cost for the year 2017. The following cost categories were included into the study: out-patient care, laboratory diagnostics, medical imaging, acute in-patient care, chronic in-patient care and drugs. Patients with lichen planus were identified with the following codes of the International Classification of Diseases 10threvision: L43. RESULTS: The number of patient underwent outpatient care was 3,013 (59.8 % women and 40.2 % men) with a mean age of 54.90 years (women: 57.56 years; men: 50.94 years). Number of patients admitted to in-patient hospital care was 145 (75.9 % women and 24.1 % men) with a mean age of 61.48 years (women: 64.42 years; men: 52.23 years). For the treatment of patients with lichen planusin 2017 the Hungarian National Health Insurance Fund Administration spent 57.282 million Hungarian Forint (HUF) which equals 185.255 Euro (EUR). Major cost drivers were acute inpatient care (35.6 % of total health insurance costs), outpatient care (28.1 %) and pharmaceuticals (26.8 %). CONCLUSIONS: Lichen planus represent a significant burden for the Hungarian health insurance system. The occurrence of the disease is more common in women both in outpatient and inpatient care. There is a significant difference (outpatient: 6.61 years; inpatient: 12.19 years) in the onset of the disease between women and men.

Hidradenitis suppurativa‐related expenditure, a call for awareness: systematic review of literature

“…Patients with Inflammatory bowel disease (IBD) and HS, had higher mean cost of hospitalization comparing to their IBD‐only counterparts ($ 1,035 absolute difference, P = 0.013) [27, 28]. Obese HS patients and those also suffering from metabolic diseases also incur higher annual costs [28]. A recent study by van Straalen et al.…”

“…Patients with Inflammatory bowel disease (IBD) and HS, had higher mean cost of hospitalization comparing to their IBD-only counterparts ($ 1,035 absolute difference, P = 0.013) [27,28]. Obese HS patients and those also suffering from metabolic diseases also incur higher annual costs [28]. A recent study by van Straalen et al showed that HS patients are more likely to be obese or overweight at disease onset compared to healthy, age-matched controls, which could potentially mean that increased weight predisposes to HS development, at least in a subgroup of patients [29].…”

“…Hidradenitis suppurativa seems to increase healthcare expenses incurred by the diseases it co-exists with [27]. Patients with Inflammatory bowel disease (IBD) and HS, had higher mean cost of hospitalization comparing to their IBD-only counterparts ($ 1,035 absolute difference, P = 0.013) [27,28]. Obese HS patients and those also suffering from metabolic diseases also incur higher annual costs [28].…”

Hidradenitis‐suppurativa‐bedingte Kosten, ein Plädoyer für Aufmerksamkeit: eine systematische Literaturübersicht

“…Patienten mit chronisch‐entzündlichen Darmerkrankungen (CED) und HS hatten höhere durchschnittliche Krankenhauskosten im Vergleich zu Patienten, die nur an CED erkrankt waren (absolute Differenz 1.035 $, P = 0,013) [27, 28]. Adipöse HS‐Patienten und Patienten mit Stoffwechselerkrankungen verursachen ebenfalls höhere jährliche Kosten [28]. Eine vor kurzem veröffentlichte Studie von van Straalen et al.…”

Early health economic modelling for a treatment candidate in hidradenitis suppurativa

“…The economic burden of HS is high, with direct medical costs due to surgery being estimated at £2,027 per patient per year in the UK [10]. Medical costs are observed to be up to 2.4 times higher for more severe HS patients [11]. Indirect costs associated with frequent and long-term A c c e p t e d M a n u s c r i p t absenteeism and disability costs of HS patients further add to the socioeconomic burden of HS [12].…”